source
- Excluding orphan drugs from Medicare pricing pilots could erase most savings, analysis showsA Harvard researcher has calculated that removing rare disease treatments from two Medicare pilot programs-GLOBE and GUARD-would dramatically cut the projected cost savings. The pilots are designe…
- Five BioSpace NextGen companies debut on US markets in 2026, four actively hiringBioSpace NextGen honorees accounted for about one third of the 14 U.S. biotech companies that went public in 2026. The five companies together raised roughly $1.5 billion in IPO proceeds, includin…